BioSpace News Archive

Hoffmann-La Roche Limited announced that it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance for VABYSMO®, indicated for the treatment of neovascular age-related macular degeneration and diabetic macular edema,1 two of the leading causes of vision loss among Canadians.

Bridge Biotherapeutics Inc., a South Korean clinical-stage biotechnology company focused on developing novel drugs for cancer, fibrosis and inflammation, is scheduled to give a company presentation on Tuesday, June 6 at the 2023 BIO International Convention taking place in Boston, Massachusetts, between June 5 - 8, 2023.

iNtRON Biotechnology has announced the identification of Prophage and ORF-Jamphage from the microbiome frequently observed in long-term Pancreatic cancer survivors.

Amplia Therapeutics Limited is pleased to announce new data showing the efficacy of its investigational FAK inhibitor, AMP945, in a preclinical model of pancreatic cancer, when used in combination with FOLFIRINOX treatment.

Hummingbird Bioscience announced a Trials in Progress poster presentation for HMBD-002, a unique anti-VISTA antibody, at the American Society of Clinical Oncology Annual Meeting being held 2-6 June, 2023 in Chicago.

Novotech, the leading Asia Pacific centred biotech CRO is sponsoring the BIO 2023 APAC Summit, and the Endpoints session on Forging New Biotech Ties with China.

RegCell collaborators from Keio University and Osaka University presented key data at ISID 2023 Tokyo Satellite Meeting.

Titan Medical Inc. announced a corporate update and is also providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 – Management Cease Trade Orders.

Immutep Limited announces it has entered into an agreement with Charles River under which Charles River will conduct a GLP toxicology study for IMP761, Immutep’s proprietary preclinical candidate for autoimmune diseases.

Extendicare Inc. announced the results of matters voted on at its annual meeting of shareholders held on May 29, 2023, which included the election as directors of the Company of all of the nominees listed in its management information and proxy circular dated April 17, 2023.